Wells Fargo & Company Y M Abs Therapeutics, Inc. Transaction History

Wells Fargo & Company

$429 Billion
Q1 2025

A detailed history of Wells Fargo & Company transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 17,852 shares of YMAB stock, worth $82,476. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,852

Previous 17,458 2.26%

Holding current value

$82,476

Previous $136,000 41.91%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$4.43 - $8.17 $1,745 - $3,218	394 Added 2.26%	17,852 $79,000
Q4 2024 Feb 12, 2025	BUY	$7.76 - $15.69 $47,576 - $96,195	6,131 Added 54.13%	17,458 $136,000
Q3 2024 Nov 13, 2024	SELL	$9.95 - $15.39 $4,467 - $6,910	-449 Reduced 3.81%	11,327 $148,000
Q2 2024 Aug 13, 2024	SELL	$11.6 - $17.25 $2,772 - $4,122	-239 Reduced 1.99%	11,776 $142,000
Q1 2024 May 10, 2024	BUY	$6.57 - $18.69 $10,393 - $29,567	1,582 Added 15.16%	12,015 $195,000
Q4 2023 Feb 09, 2024	BUY	$4.88 - $7.42 $10,745 - $16,338	2,202 Added 26.75%	10,433 $71,000
Q3 2023 Nov 13, 2023	SELL	$4.86 - $7.23 $31,040 - $46,178	-6,387 Reduced 43.69%	8,231 $44,000
Q2 2023 Aug 15, 2023	BUY	$5.68 - $10.34 $42,878 - $78,056	7,549 Added 106.79%	14,618 $99,000
Q1 2023 May 12, 2023	BUY	$2.83 - $5.11 $20,005 - $36,122	7,069 New	7,069 $35,000
Q3 2022 Nov 14, 2022	SELL	$13.96 - $19.67 $3,378 - $4,760	-242 Reduced 15.79%	1,291 $18,000
Q2 2022 Aug 12, 2022	SELL	$8.22 - $15.13 $134,429 - $247,436	-16,354 Reduced 91.43%	1,533 $23,000
Q1 2022 May 16, 2022	SELL	$6.55 - $17.42 $72,560 - $192,978	-11,078 Reduced 38.25%	17,887 $212,000
Q4 2021 Feb 14, 2022	SELL	$15.51 - $29.31 $204,080 - $385,660	-13,158 Reduced 31.24%	28,965 $470,000
Q3 2021 Nov 15, 2021	BUY	$27.47 - $37.31 $701,116 - $952,263	25,523 Added 153.75%	42,123 $1.2 Million
Q2 2021 Aug 16, 2021	BUY	$25.45 - $37.64 $56,651 - $83,786	2,226 Added 15.49%	16,600 $562,000
Q1 2021 May 13, 2021	SELL	$29.16 - $51.96 $364,820 - $650,071	-12,511 Reduced 46.54%	14,374 $435,000
Q4 2020 Feb 09, 2021	BUY	$37.86 - $54.26 $396,053 - $567,613	10,461 Added 63.69%	26,885 $1.33 Million
Q3 2020 Nov 05, 2020	SELL	$35.13 - $43.62 $66,184 - $82,180	-1,884 Reduced 10.29%	16,424 $632,000
Q2 2020 Aug 13, 2020	BUY	$23.66 - $49.53 $135,335 - $283,311	5,720 Added 45.44%	18,308 $791,000
Q1 2020 May 14, 2020	BUY	$14.39 - $35.8 $181,141 - $450,650	12,588 New	12,588 $329,000

Others Institutions Holding YMAB

# of Institutions

105

Shares Held

27.1M

Call Options Held

38.4K

Put Options Held

2.1K

View Full List

About Y-mAbs Therapeutics, Inc.

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $202M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

More about YMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Y M Abs Therapeutics, Inc. Transaction History